In this edition:
– All-cause mortality for torsemide vs. furosemide after HF hospitalisation
– Is exercise capacity limited by elevated PCWP in HFPEF?
– Association of anthracycline exposure with HF
– Sociodemographic differences in HFREF medical therapy
– Effects of His bundle pacing on HF symptoms and exercise capacity
– Cost effectiveness of immediate dapagliflozin in patients with HF history
– Association of PCSK9 loss-offunction variants with HF risk
– Transcriptomic and proteomic profiles identify HF patients with potential for myocardial recovery
– Prognostic implications of PVP-assessed post-discharge haemodynamic congestion after acute HF
– Sex differences in response to dapagliflozin for HF across the EF spectrum